SIGN ON LETTER to global actors and drug companies: Please provide organizational sign-ons by 6 March.

Several organizations and individuals working on TB are concerned that some medical schemes may be refusing to cover the cost of linezolid for drug-resistant tuberculosis.

Earlier this year, the Global Fund started a full roll out of its new funding model. In March 2014 at its Thirty-First Meeting the Global Fund Board approved a new allocation methodology and the funding resources for the 2014 - 2016 allocation period. 24 organizations representing civil society and including communities of people living with HIV, tuberculosis (TB) or Hepatitis C, i.e. key affected populations from Eastern Europe and Central Asia (EECA) and their partner organizations from other regions signed an Open Letter addressed to the Global Fund Board members.

A letter, signed by over 100 clinicians, organisations and patients with DR-TB, demands the immediate registration of a generic version of linezolid in South Africa, which has been under a significantly delayed fast-track review process since May 2013.

Today TB activists interrupted the plenary session at the 45^th Conference on Lung Health, calling on the Global Fund and partners to increase the amount of funds allocated to TB without jeopardizing funding to HIV and malaria and other diseases.

Today at the opening plenary of the 45^th Conference on Lung Health in Barcelona, activists from across the globe called on governments to dramatically increase spending on R&D for new treatments for TB. Spending must be tripled to meet the US$2 billion annual minimum required according to the Stop TB Partnership’s Global Plan to Stop TB.

Community members, patient advocates and civil society members and representatives from affected communities express their disappointment with the Union's scholarship programme.

Several organizations and individuals working on TB appeal to Janssen to lower bedaquiline's price for all non-high-income countries.